Does PT-141 Work for Women’s Libido?

PT-141 is bremelanotide, also known by the brand name Vyleesi. In two phase 3 placebo-controlled trials, premenopausal women with hypoactive sexual desire disorder (HSDD) reported statistically significant improvements in sexual desire and less distress related to low desire compared with placebo.

That does not make it a universal libido booster. The research studied a specific pattern: persistent, acquired, generalized low desire that causes meaningful personal distress. If your desire has gone flat after stress, childbirth, medication changes, or shifting hormones, the cause still matters. PT-141 may fit some women, but it is not a promise of more energy, higher hormone levels, or instant sexual motivation.

What PT-141 is

PT-141 is the peptide name for bremelanotide, a melanocortin-receptor agonist. It acts primarily through brain pathways involved in sexual motivation rather than by increasing genital blood flow.

A 2022 review in CNS Spectrums identifies MC4R as the most relevant melanocortin receptor at therapeutic doses. MC4R is concentrated in the medial preoptic area of the hypothalamus. Animal research suggests that activating presynaptic MC4R in this area may increase dopamine release, a signal involved in sexual desire.

The FDA approved bremelanotide injection in 2019 for acquired, generalized HSDD in premenopausal women. HSDD describes low sexual desire that persists, causes marked personal distress, and is not better explained by another medical, medication-related, psychological, or relationship factor. The approval and clinical trials therefore apply to a defined condition, not every temporary dip in interest.

Does PT-141 work for women’s libido?

The main clinical evidence comes from the two RECONNECT phase 3 trials published in Obstetrics & Gynecology in 2019. The studies were randomized, double-blind, placebo-controlled trials involving premenopausal women diagnosed with HSDD.

Researchers measured two primary outcomes:

• Change in the desire domain of the Female Sexual Function Index (FSFI-desire).
• Change in item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm, which measures distress related to low desire.

Compared with placebo, the bremelanotide groups showed these differences:

• In study 301, FSFI-desire improved by 0.30 points, with P < .001.
• In study 302, FSFI-desire improved by 0.42 points, with P < .001.
• Across both trials, the integrated improvement was 0.35 points, with P < .001.
• Desire-related distress fell by 0.37 points in one trial, 0.29 points in the other, and 0.33 points across both trials. Each result had P < .001.

Those results show a measurable average difference on validated sexual-function scales. They do not mean every woman will feel a dramatic change, and they do not show that PT-141 raises energy or corrects a hormone problem. The participants had HSDD, so the results should not be stretched to cover every kind of low desire.

If you are weighing bremelanotide against another prescription option, see PT-141 vs. Addyi for low libido for a focused comparison of the two medications.

How PT-141 was used in the trials

The RECONNECT studies evaluated a 1.75 mg subcutaneous injection used as needed, rather than a fixed daily treatment. Participants used it in connection with anticipated sexual activity, and the blinded treatment period lasted 24 weeks. The trial record also included an optional open-label extension.

The published trial report and ClinicalTrials.gov record describe the study design. A prescriber decides whether the approach studied in those trials is appropriate for you and reviews timing, frequency limits, and safety before treatment.

Side effects and safety questions

Nausea is the side effect readers hear about most often. An Inner Circle Labs overview reports nausea in about 40% of users, flushing in 20%, and headache in 11%. Injection-site reactions are also reported.

Other issues to discuss with a prescriber include temporary blood-pressure increases and focal hyperpigmentation, which can occur with repeated injections. Your cardiovascular history, current medications, history of nausea, and any tendency toward skin pigmentation changes all belong in that conversation.

The point is not to scare yourself out of considering PT-141. It is to be honest about the tradeoff. A medication that helps desire but makes you too nauseated to enjoy sex is not doing its job for you.

Who was studied, and who should ask more questions?

You are closer to the population studied if your low desire:

• Persisted after a period of normal sexual function.
• Feels generalized rather than limited to one partner or situation.
• Causes personal distress.
• Occurs while you are premenopausal.

The RECONNECT trials enrolled premenopausal women with HSDD. They do not establish the same evidence for postmenopausal women, men, or concerns focused mainly on energy, mood, or hormone levels.

Get Hot or Die currently prescribes and dispenses medication when appropriate. Specific HOD medication pricing, coverage, and fulfillment details were not available for this comparison. Get Hot or Die personalized quiz can help organize your desire pattern, medical background, and goals before you discuss options with a care team.

Sources

• Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics & Gynecology. 2019. PubMed
• “The Neurobiology of Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women.” CNS Spectrums. 2022. Cambridge Core and PubMed
• ClinicalTrials.gov study NCT02333071
• Inner Circle Labs PT-141 overview

FAQ: PT-141 for women

What is PT-141 and how does it work?

PT-141 is bremelanotide, a melanocortin-receptor agonist. Research describes MC4R activity in the hypothalamus as a possible part of how it influences sexual motivation and dopamine signaling.

Does PT-141 work for women’s libido?

In two phase 3 trials, bremelanotide improved sexual desire and reduced distress related to low desire in premenopausal women with HSDD. The integrated difference versus placebo was 0.35 points for desire and -0.33 points for distress.

How was PT-141 used in clinical studies?

The RECONNECT studies evaluated a 1.75 mg subcutaneous injection used as needed, often about 45 minutes before anticipated sexual activity, over a 24-week blinded treatment period. A prescriber determines whether that studied approach is appropriate.

What side effects can PT-141 cause?

Reported effects include nausea, flushing, headache, injection-site reactions, temporary blood-pressure increases, and focal hyperpigmentation with repeated use. A cited overview reported nausea in about 40% of users, flushing in 20%, and headache in 11%.

Could PT-141 fit my low desire?

The closest studied pattern is persistent, acquired, generalized low desire that causes personal distress in a premenopausal woman with HSDD. A clinician can review whether your symptoms and health history fit that evidence.